Physiological effects of oral glucosamine on joint health: Current status and consensus on future research priorities

被引：26
作者：
Henrotin Y. [1 ,2 ]
Chevalier X. [3 ]
Herrero-Beaumont G. [4 ]
McAlindon T. [5 ]
Mobasheri A. [6 ]
Pavelka K. [7 ]
Schön C. [8 ]
Weinans H. [9 ]
Biesalski H. [10 ]
机构：
[1] Bone and Cartilage Research Unit, University of Liège, Institute of Pathology
[2] Princess Paola Hospital, Marche-en-Famenne
[3] Rheumatology Department, Mondor Hospital, Créteil
[4] Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid
[5] Division of Rheumatology, Tufts Medical Center, Boston, MA 02111
[6] Division of Veterinary Medicine, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, Leicestershire
[7] Institute of Rheumatology, Prague
[8] UMC Utrecht, Department of Orthopedics, Utrecht 3584 CX
[9] Erasmus University Medical Center, Rotterdam
[10] Department of Biological Chemistry and Nutrition, Stuttgart D 70593
来源：
BMC Research Notes | / 6卷 / 1期
基金：
英国工程与自然科学研究理事会; 英国生物技术与生命科学研究理事会; 英国惠康基金; 英国国家替代、减少和改良动物研究中心;
关键词：
Glucosamine; Osteoarthritis; Prevention; Treatment;
D O I：
10.1186/1756-0500-6-115
中图分类号：
学科分类号：
摘要：
The aim of this paper was to provide an overview of the current knowledge and understanding of the potential beneficial physiological effects of glucosamine (GlcN) on joint health. The objective was to reach a consensus on four critical questions and to provide recommendations for future research priorities. To this end, nine scientists from Europe and the United States were selected according to their expertise in this particular field and were invited to participate in the Hohenheim conference held in August 2011. Each expert was asked to address a question that had previously been posed by the chairman of the conference. Based on a systematic review of the literature and the collection of recent data, the experts documented the effects of GlcN on cartilage ageing, metabolic/kinetic and maintenance of joint health as well as reduction of risk of OA development. After extensive debate and discussion the expert panel addressed each question and a general consensus statement was developed, agreeing on the current state-of-the-art and future areas for basic and clinical studies. This paper summarizes the available evidence for beneficial effects of GlcN on joint health and proposes new insight into the design of future clinical trials aimed at identifying beneficial physiological effect of GlcN on joint tissues. © 2013Henrotin et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 85 条
  • [31] Hinderlich S., Berger M., Schwarzkopf M., Effertz K., Reutter W., Molecular cloning and characterization of murine and human N-acetylglucosamine kinase, Eur J Biochem, 267, pp. 3301-3308, (2000)
  • [32] Block J.A., Oegema T.R., Sandy J.D., Plaas A., The effects of oral glucosamine on joint health: Is a change in research approach needed?, Osteoarthr Cartil, 18, pp. 5-11, (2010)
  • [33] Hubert C., Houari S., Lecomte F., Houbart V., De Bleye C., Fillet M., Piel G., Rozet E., Hubert P., Development and validation of a sensitive solid phase extraction/hydrophilic interaction liquid chromatography/mass spectrometry method for the accurate determination of glucosamine in dog plasma, J Chromatogr A, 1217, pp. 3275-3281, (2010)
  • [34] Roda A., Sabatini L., Barbieri A., Guardigli M., Locatelli M., Violante F.S., Rovati L.C., Persiani S., Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma, J Chromatogr B Analyt Technol Biomed Life Sci, 844, pp. 119-126, (2006)
  • [35] Persiani S., Roda E., Rovati L.C., Locatelli M., Giacovelli G., Roda A., Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man, Osteoarthr Cartil, 13, pp. 1041-1049, (2005)
  • [36] Biggee B.A., Blinn C.M., Nuite M., McAlindon T.E., Silbert J.E., Changes in serum levels of glucosamine and sulphate after ingestion of glucosamine sulphate with and without simultaneous ingestion of glucose, Ann Rheum Dis, 66, pp. 1403-1404, (2007)
  • [37] Zhong S., Zhong D., Chen X., Improved and simplified liquid chromatography/electrospray ionization mass spectrometry method for the analysis of underivatized glucosamine in human plasma, J Chromatogr B Analyt Technol Biomed Life Sci, 854, pp. 291-298, (2007)
  • [38] Laverty S., Sandy J.D., Celeste C., Vachon P., Marier J.F., Plaas A.H., Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses, Arthritis Rheum, 52, pp. 181-191, (2005)
  • [39] Persiani S., Rotini R., Trisolino G., Rovati L.C., Locatelli M., Paganini D., Antonioli D., Roda A., Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose, Osteoarthr Cartil, 15, pp. 764-772, (2007)
  • [40] Pastorini E., Rotini R., Guardigli M., Vecchiotti S., Persiani S., Trisolino G., Antonioli D., Rovati L.C., Roda A., Development and validation of a HPLC-ES-MS/MS method for the determination of glucosamine in human synovial fluid, J Pharm Biomed Anal, 50, pp. 1009-1014, (2009)
123456789